Biotech 2050 Podcast

Co-creating Breakthroughs in R&D: Paul Biondi (Flagship) & Uli Stilz (Novo Nordisk)


Listen Later

Synopsis:
When biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship Pioneering, and Uli Stilz, Vice President, R&D External Innovation Partners at Novo Nordisk, to explore the power of co-creation.
Together, they unpack how Flagship’s pioneering medicines model and Novo’s Bio Innovation Hub intersect to accelerate breakthroughs in obesity, diabetes, and cardiometabolic diseases. They share lessons on building trust, navigating crises, and structuring alliances that go beyond transactions into enduring innovation ecosystems.
From human disease atlases to new frameworks for agile collaboration, this episode offers a rare behind-the-scenes look at how pharma and biotech can partner differently—turning complexity into transformative therapies.
Biography:
Paul Biondi is a Managing Partner at Flagship Pioneering, leading Flagship’s product and partnering capabilities, including Pioneering Medicines, Partnering, and Pipeline and Product Innovation.
In this role, Paul oversees Pioneering Medicines, Flagship's in-house drug discovery and development unit, as well as therapeutic partnering and business development efforts for the Flagship ecosystem, including driving broad institution-wide Innovation Supply Chain partnerships with biopharma companies to jointly conceive and create innovative products.
Paul also works with Flagship company CEOs and their teams to achieve the best attainable value for each company, guiding them in their pipeline strategy, product concepts, R&D execution, and partnering approach. He serves on the boards of Flagship-founded companies, including Tessera Technologies (NASDAQ: TSRA) and Valo Health.
Paul Biondi is Managing Partner at Flagship Pioneering, joining after 17 years at Bristol-Myers Squibb (BMS), where he served as SVP of Strategy & Business Development and held leadership roles in R&D. He previously spent nine years at Mercer Management Consulting. Paul earned his MBA from the Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College.
Uli Stilz is Corporate Vice President, R&D External Innovation Partners, External & Exploratory Innovation (E2I) at Novo Nordisk., based in Boston. He leads a global R&D team that builds creative partnerships with biotech, venture capital, academia, and research hospitals to co-create next-generation therapeutics in cardiometabolic and rare diseases. Building on the success of the Novo Nordisk Bio Innovation Hub, Uli and the E2I team drive an externally anchored portfolio of collaborations that stimulate global innovation ecosystems and advance Novo Nordisk’s pipeline.
Uli Stilz earned his Master’s in Organic Chemistry from ETH Zürich and a Ph.D. in Biochemistry from the Max-Planck-Institute of Biochemistry in Martinsried, followed by postdoctoral research at Caltech. He began his industry career at Hoechst AG and later Sanofi, where he became Associate VP of the Innovation Unit in the Diabetes Division. Over two decades, he contributed to more than 60 preclinical and clinical drug candidates in cardiometabolic, immunology, and oncology. From 2012–2014, he served as President of the European Federation for Medicinal Chemistry.
In 2014, Uli joined Novo Nordisk in Copenhagen and in 2019 moved to Boston to establish and lead the Bio Innovation Hub, now the External & Exploratory Innovation (E2I) organization. He also serves as Adjunct Professor at the University of Frankfurt, sits on editorial and scientific advisory boards, and holds board roles at the Kendall Square Association and Gensaic, while advising the aMoon Fund.
...more
View all episodesView all episodes
Download on the App Store

Biotech 2050 PodcastBy Biotech 2050

  • 4.8
  • 4.8
  • 4.8
  • 4.8
  • 4.8

4.8

60 ratings


More shows like Biotech 2050 Podcast

View all
a16z Podcast by Andreessen Horowitz

a16z Podcast

1,083 Listeners

The Bio Report by Levine Media Group

The Bio Report

41 Listeners

The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch by Harry Stebbings

The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

527 Listeners

Y Combinator Startup Podcast by Y Combinator

Y Combinator Startup Podcast

223 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

125 Listeners

The Readout Loud by STAT

The Readout Loud

325 Listeners

All-In with Chamath, Jason, Sacks & Friedberg by All-In Podcast, LLC

All-In with Chamath, Jason, Sacks & Friedberg

9,816 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

86 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

33 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

145 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

20 Listeners

Beyond Biotech - the podcast from Labiotech by Labiotech

Beyond Biotech - the podcast from Labiotech

3 Listeners

The Biotech Startups Podcast by Excedr

The Biotech Startups Podcast

23 Listeners

The Top Line by Fierce Life Sciences

The Top Line

14 Listeners

The BioCentury Show by BioCentury

The BioCentury Show

11 Listeners